Exact Mass: 540.2404

Atorvastatin lactone

C33H33FN2O4 (540.2424)

Methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethyl-1-oxopentyl)-4-hydroxy-6,7,8-trimethoxy-2-naphthalenecarboxylate

C30H36O9 (540.2359)

PA(2:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

C27H41O9P (540.2488)

PA(2:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 4-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

C27H41O9P (540.2488)

PA(2:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 7-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/2:0)

C27H41O9P (540.2488)

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/2:0), in particular, consists of one chain of one 7-hydroxy-docosahexaenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

C27H41O9P (540.2488)

PA(2:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 14-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/2:0)

C27H41O9P (540.2488)

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/2:0), in particular, consists of one chain of one 14-hydroxy-docosahexaenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

C27H41O9P (540.2488)

PA(2:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 17-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/2:0)

C27H41O9P (540.2488)

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/2:0), in particular, consists of one chain of one 17-hydroxy-docosahexaenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

C27H41O9P (540.2488)

PA(2:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 16,17-epoxy-docosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/2:0)

C27H41O9P (540.2488)

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/2:0), in particular, consists of one chain of one 16,17-epoxy-docosapentaenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

Pulcherrin C

C30H36O9 (540.2359)

Zumketol

C30H36O9 (540.2359)

Sesquipinsapol B

C30H36O9 (540.2359)

Norstaminone A

C30H36O9 (540.2359)

SCHEMBL1111341

C30H36O9 (540.2359)

6alpha-Acetoxygedunin

C30H36O9 (540.2359)

2alpha-senecioyloxy-3alpha-angeloyloxy-3,4-betaH-bacchotricuneatin

C30H36O9 (540.2359)

11beta-Acetoxygedunin

C30H36O9 (540.2359)

dichrocepholide D

C30H36O9 (540.2359)

dumsenin

C30H36O9 (540.2359)

andirolide A

C30H36O9 (540.2359)

peniciketal A

C30H36O9 (540.2359)

aurisin A

C30H36O9 (540.2359)

11beta,12alpha-diacetoxy-14beta,15beta-epoxyneotecleanin|11??,12??-Diacetoxy-14??,15??-epoxyneotecleanin|zumsin

C30H36O9 (540.2359)

(20S,22S,23S,24S,25S,26S)-5alpha-chloro-12alpha,22-23,26,24,25-triepoxy-6beta,12beta,17beta,26-tetrahydroxyergosta-1-one|jaborosalactol 26

C28H41ClO8 (540.249)

2alpha-angeloyloxy-3alpha-senecioyloxy-3,4-betaH-bacchotricuneatin

C30H36O9 (540.2359)

isonimolicinolide

C30H36O9 (540.2359)

Nimbin_(chemical)

C30H36O9 (540.2359)

Nimbin is a limonoid found in Azadirachta indica. It has a role as a plant metabolite and a pesticide. It is an acetate ester, a limonoid, a member of furans, a cyclic terpene ketone, an enone, a tetracyclic triterpenoid and a methyl ester. Nimbin is a natural product found in Azadirachta indica with data available. A limonoid found in Azadirachta indica.

C30H36O9_2H-Cyclopenta[b]naphtho[2,3-d]furan-10-acetic acid, 5-(acetyloxy)-2-(3-furanyl)-3,3a,4a,5,5a,6,9,9a,10,10a-decahydro-6-(methoxycarbonyl)-1,6,9a,10a-tetramethyl-9-oxo-, methyl ester, (2R,3aR,4aS,5R,6R,9aR,10S,10aR)

C30H36O9 (540.2359)

methyl (1S,2R,4R,8R,9S,10R,13R,15R)-2-(acetyloxy)-13-(furan-3-yl)-9-(2-methoxy-2-oxoethyl)-4,8,10,12-tetramethyl-7-oxo-16-oxatetracyclo[8.6.0.0³,⁸.0¹¹,¹⁵]hexadeca-5,11-diene-4-carboxylate

C30H36O9 (540.2359)

methyl (1S,2R,4R,8R,9S,10R,13R,15R)-2-(acetyloxy)-13-(furan-3-yl)-9-(2-methoxy-2-oxoethyl)-4,8,10,12-tetramethyl-7-oxo-16-oxatetracyclo[8.6.0.0³,⁸.0¹¹,¹⁵]hexadeca-5,11-diene-4-carboxylate_major

C30H36O9 (540.2359)

methyl (1S,2R,4R,8R,9S,10R,13R,15R)-2-(acetyloxy)-13-(furan-3-yl)-9-(2-methoxy-2-oxoethyl)-4,8,10,12-tetramethyl-7-oxo-16-oxatetracyclo[8.6.0.0³,?.0¹¹,¹?]hexadeca-5,11-diene-4-carboxylate

C30H36O9 (540.2359)

Ala His Gln Trp

C25H32N8O6 (540.2445)

Ala His Trp Gln

C25H32N8O6 (540.2445)

Ala Gln His Trp

C25H32N8O6 (540.2445)

Ala Gln Trp His

C25H32N8O6 (540.2445)

Ala Trp His Gln

C25H32N8O6 (540.2445)

Ala Trp Gln His

C25H32N8O6 (540.2445)

Cys Lys Gln Tyr

C23H36N6O7S (540.2366)

Cys Lys Tyr Gln

C23H36N6O7S (540.2366)

Cys Gln Lys Tyr

C23H36N6O7S (540.2366)

Cys Gln Tyr Lys

C23H36N6O7S (540.2366)

Cys Tyr Lys Gln

C23H36N6O7S (540.2366)

Cys Tyr Gln Lys

C23H36N6O7S (540.2366)

Asp His Asn Arg

C20H32N10O8 (540.2404)

Asp His Arg Asn

C20H32N10O8 (540.2404)

Asp Asn His Arg

C20H32N10O8 (540.2404)

Asp Asn Arg His

C20H32N10O8 (540.2404)

Asp Arg His Asn

C20H32N10O8 (540.2404)

Asp Arg Asn His

C20H32N10O8 (540.2404)

Phe Phe Met Pro

C28H36N4O5S (540.2406)

Phe Phe Asn Asn

C26H32N6O7 (540.2332)

Phe Phe Pro Met

C28H36N4O5S (540.2406)

Phe His His Thr

C25H32N8O6 (540.2445)

Phe His Thr His

C25H32N8O6 (540.2445)

Phe Ile Met Met

C25H40N4O5S2 (540.244)

Phe Leu Met Met

C25H40N4O5S2 (540.244)

Phe Met Phe Pro

C28H36N4O5S (540.2406)

Phe Met Ile Met

C25H40N4O5S2 (540.244)

Phe Met Leu Met

C25H40N4O5S2 (540.244)

Phe Met Met Ile

C25H40N4O5S2 (540.244)

Phe Met Met Leu

C25H40N4O5S2 (540.244)

Phe Met Pro Phe

C28H36N4O5S (540.2406)

Phe Asn Phe Asn

C26H32N6O7 (540.2332)

Phe Asn Asn Phe

C26H32N6O7 (540.2332)

Phe Pro Phe Met

C28H36N4O5S (540.2406)

Phe Pro Met Phe

C28H36N4O5S (540.2406)

Phe Thr His His

C25H32N8O6 (540.2445)

His Ala Gln Trp

C25H32N8O6 (540.2445)

His Ala Trp Gln

C25H32N8O6 (540.2445)

His Asp Asn Arg

C20H32N10O8 (540.2404)

His Asp Arg Asn

C20H32N10O8 (540.2404)

His Phe His Thr

C25H32N8O6 (540.2445)

His Phe Thr His

C25H32N8O6 (540.2445)

His His Phe Thr

C25H32N8O6 (540.2445)

His His Thr Phe

C25H32N8O6 (540.2445)

His Asn Asp Arg

C20H32N10O8 (540.2404)

His Asn Arg Asp

C20H32N10O8 (540.2404)

His Gln Ala Trp

C25H32N8O6 (540.2445)

His Gln Trp Ala

C25H32N8O6 (540.2445)

His Arg Asp Asn

C20H32N10O8 (540.2404)

His Arg Asn Asp

C20H32N10O8 (540.2404)

His Thr Phe His

C25H32N8O6 (540.2445)

His Thr His Phe

C25H32N8O6 (540.2445)

His Trp Ala Gln

C25H32N8O6 (540.2445)

His Trp Gln Ala

C25H32N8O6 (540.2445)

Ile Phe Met Met

C25H40N4O5S2 (540.244)

Ile Met Phe Met

C25H40N4O5S2 (540.244)

Ile Met Met Phe

C25H40N4O5S2 (540.244)

Lys Cys Gln Tyr

C23H36N6O7S (540.2366)

Lys Cys Tyr Gln

C23H36N6O7S (540.2366)

Lys Gln Cys Tyr

C23H36N6O7S (540.2366)

Lys Gln Tyr Cys

C23H36N6O7S (540.2366)

Lys Tyr Cys Gln

C23H36N6O7S (540.2366)

Lys Tyr Gln Cys

C23H36N6O7S (540.2366)

Leu Phe Met Met

C25H40N4O5S2 (540.244)

Leu Met Phe Met

C25H40N4O5S2 (540.244)

Leu Met Met Phe

C25H40N4O5S2 (540.244)

Met Phe Phe Pro

C28H36N4O5S (540.2406)

Met Phe Ile Met

C25H40N4O5S2 (540.244)

Met Phe Leu Met

C25H40N4O5S2 (540.244)

Met Phe Met Ile

C25H40N4O5S2 (540.244)

Met Phe Met Leu

C25H40N4O5S2 (540.244)

Met Phe Pro Phe

C28H36N4O5S (540.2406)

Met Ile Phe Met

C25H40N4O5S2 (540.244)

Met Ile Met Phe

C25H40N4O5S2 (540.244)

Met Leu Phe Met

C25H40N4O5S2 (540.244)

Met Leu Met Phe

C25H40N4O5S2 (540.244)

Met Met Phe Ile

C25H40N4O5S2 (540.244)

Met Met Phe Leu

C25H40N4O5S2 (540.244)

Met Met Ile Phe

C25H40N4O5S2 (540.244)

Met Met Leu Phe

C25H40N4O5S2 (540.244)

Met Pro Phe Phe

C28H36N4O5S (540.2406)

Asn Asp His Arg

C20H32N10O8 (540.2404)

Asn Asp Arg His

C20H32N10O8 (540.2404)

Asn Phe Phe Asn

C26H32N6O7 (540.2332)

Asn Phe Asn Phe

C26H32N6O7 (540.2332)

Asn His Asp Arg

C20H32N10O8 (540.2404)

Asn His Arg Asp

C20H32N10O8 (540.2404)

Asn Asn Phe Phe

C26H32N6O7 (540.2332)

Asn Arg Asp His

C20H32N10O8 (540.2404)

Asn Arg His Asp

C20H32N10O8 (540.2404)

Pro Phe Phe Met

C28H36N4O5S (540.2406)

Pro Phe Met Phe

C28H36N4O5S (540.2406)

Pro Met Phe Phe

C28H36N4O5S (540.2406)

Gln Ala His Trp

C25H32N8O6 (540.2445)

Gln Ala Trp His

C25H32N8O6 (540.2445)

Gln Cys Lys Tyr

C23H36N6O7S (540.2366)

Gln Cys Tyr Lys

C23H36N6O7S (540.2366)

Gln His Ala Trp

C25H32N8O6 (540.2445)

Gln His Trp Ala

C25H32N8O6 (540.2445)

Gln Lys Cys Tyr

C23H36N6O7S (540.2366)

Gln Lys Tyr Cys

C23H36N6O7S (540.2366)

Gln Trp Ala His

C25H32N8O6 (540.2445)

Gln Trp His Ala

C25H32N8O6 (540.2445)

Gln Tyr Cys Lys

C23H36N6O7S (540.2366)

Gln Tyr Lys Cys

C23H36N6O7S (540.2366)

Arg Asp His Asn

C20H32N10O8 (540.2404)

Arg Asp Asn His

C20H32N10O8 (540.2404)

Arg His Asp Asn

C20H32N10O8 (540.2404)

Arg His Asn Asp

C20H32N10O8 (540.2404)

Arg Asn Asp His

C20H32N10O8 (540.2404)

Arg Asn His Asp

C20H32N10O8 (540.2404)

Thr Phe His His

C25H32N8O6 (540.2445)

Thr His Phe His

C25H32N8O6 (540.2445)

Thr His His Phe

C25H32N8O6 (540.2445)

Trp Ala His Gln

C25H32N8O6 (540.2445)

Trp Ala Gln His

C25H32N8O6 (540.2445)

Trp His Ala Gln

C25H32N8O6 (540.2445)

Trp His Gln Ala

C25H32N8O6 (540.2445)

Trp Gln Ala His

C25H32N8O6 (540.2445)

Trp Gln His Ala

C25H32N8O6 (540.2445)

Tyr Cys Lys Gln

C23H36N6O7S (540.2366)

Tyr Cys Gln Lys

C23H36N6O7S (540.2366)

Tyr Lys Cys Gln

C23H36N6O7S (540.2366)

Tyr Lys Gln Cys

C23H36N6O7S (540.2366)

Tyr Gln Cys Lys

C23H36N6O7S (540.2366)

Tyr Gln Lys Cys

C23H36N6O7S (540.2366)

Atorvastatin lactone

C33H33FN2O4 (540.2424)

Atorvastatin lactone is a proagent form of atorvastatin. Atorvastatin is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor[1].

(2S,3S)-3-AMINO-2-HYDROXYHEPTANOICACID

C34H36O4S (540.2334)

Methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethyl-1-oxopentyl)-4-hydroxy-6,7,8-trimethoxy-2-naphthalenecarboxylate

C30H36O9 (540.2359)

PA(2:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

C27H41O9P (540.2488)

PA(2:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

C27H41O9P (540.2488)

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/2:0)

C27H41O9P (540.2488)

PA(2:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

C27H41O9P (540.2488)

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/2:0)

C27H41O9P (540.2488)

PA(2:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

C27H41O9P (540.2488)

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/2:0)

C27H41O9P (540.2488)

PA(2:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

C27H41O9P (540.2488)

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/2:0)

C27H41O9P (540.2488)

(1R)-1-(benzenesulfonyl)-1-(hydroxymethyl)-7-methoxy-9-methyl-N-propyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]carboxamide

C28H36N4O5S (540.2406)

(1S)-1-(benzenesulfonyl)-1-(hydroxymethyl)-7-methoxy-9-methyl-N-propyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]carboxamide

C28H36N4O5S (540.2406)

PA 18:4/6:2;O

C27H41O9P (540.2488)

PA 20:5/4:1;O

C27H41O9P (540.2488)

PA 24:6;O

C27H41O9P (540.2488)

PEth 22:6;O

C27H41O9P (540.2488)

PM 23:6;O

C27H41O9P (540.2488)

ST 27:4;O6;S

C27H40O9S (540.2393)

(1r,4br,5s,6r,6ar,10ar,10br,12ar)-5-(acetyloxy)-1-(furan-3-yl)-1-hydroxy-4b,7,7,10a,12a-pentamethyl-3,8-dioxo-5h,6h,6ah,10bh,11h,12h-naphtho[2,1-f]isochromen-6-yl acetate

C30H36O9 (540.2359)

methyl (3s,4as,5r,6r,6ar,7s,11as,11br)-6-(acetyloxy)-3-(benzoyloxy)-4a,5-dihydroxy-4,4,11b-trimethyl-1h,2h,3h,5h,6h,6ah,7h,11h,11ah-phenanthro[3,2-b]furan-7-carboxylate

C30H36O9 (540.2359)

20-(acetyloxy)-17-(furan-3-yl)-8,8,12,18-tetramethyl-4,11-dioxo-7,14-dioxahexacyclo[10.8.0.0²,⁶.0²,⁹.0¹³,¹⁵.0¹³,¹⁸]icosan-19-yl acetate

C30H36O9 (540.2359)

3-(2-{6a-hydroxy-6,9a-dimethyl-2,9-dioxo-4h,5h,6h,9bh-azuleno[4,5-b]furan-3-yl}ethyl)-3,6a-dihydroxy-6,9a-dimethyl-3ah,4h,5h,6h,9bh-azuleno[4,5-b]furan-2,9-dione

C30H36O9 (540.2359)

(1s,2r,4s,7s,8s,10s,11r,12s,17r,19r)-19-(acetyloxy)-7-(furan-3-yl)-1,8,12,16,16-pentamethyl-5,15-dioxo-3,6-dioxapentacyclo[9.8.0.0²,⁴.0²,⁸.0¹²,¹⁷]nonadec-13-en-10-yl acetate

C30H36O9 (540.2359)

(1r,2r,6s,9r,12r,13r,15r,17s,18r,19r,20r)-20-(acetyloxy)-17-(furan-3-yl)-8,8,12,18-tetramethyl-4,11-dioxo-7,14-dioxahexacyclo[10.8.0.0²,⁶.0²,⁹.0¹³,¹⁵.0¹³,¹⁸]icosan-19-yl acetate

C30H36O9 (540.2359)

methyl 2-{2-[4,5-bis(acetyloxy)-3-(furan-3-yl)-3a-methyl-7-methylidene-hexahydroindeno[1,7a-b]oxiren-6-yl]-6,6-dimethyl-5-oxocyclohex-3-en-1-yl}acetate

C30H36O9 (540.2359)

(3s,3ar,6s,6as,9as,9br)-3-{2-[(6s,6as,9as,9br)-6a-hydroxy-6,9a-dimethyl-2,9-dioxo-4h,5h,6h,9bh-azuleno[4,5-b]furan-3-yl]ethyl}-3,6a-dihydroxy-6,9a-dimethyl-3ah,4h,5h,6h,9bh-azuleno[4,5-b]furan-2,9-dione

C30H36O9 (540.2359)

6-(acetyloxy)-1-(furan-3-yl)-1-hydroxy-4b,7,7,10a,12a-pentamethyl-3,8-dioxo-5h,6h,6ah,10bh,11h,12h-naphtho[2,1-f]isochromen-5-yl acetate

C30H36O9 (540.2359)

methyl 6-(acetyloxy)-3-(benzoyloxy)-4a,5-dihydroxy-4,4,11b-trimethyl-1h,2h,3h,5h,6h,6ah,7h,11h,11ah-phenanthro[3,2-b]furan-7-carboxylate

C30H36O9 (540.2359)

(1s,2s,4s,6s,9r,12r,16s,17s,18r,19r)-19-(acetyloxy)-16-(furan-3-yl)-4-hydroxy-8,8,12,17-tetramethyl-3,11-dioxo-7-oxapentacyclo[10.7.0.0²,⁶.0²,⁹.0¹³,¹⁷]nonadec-13-en-18-yl acetate

C30H36O9 (540.2359)

6-hydroxy-9-{6-hydroxy-4-isopropyl-3-oxo-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-9-yl}-4-methyl-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

C30H32N6O4 (540.2485)

(1s,4r,7r,9s)-6-hydroxy-9-[(1r,4s,7s)-6-hydroxy-4-methyl-3-oxo-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-9-yl]-4-isopropyl-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

C30H32N6O4 (540.2485)

methyl 2-[(1r)-2-[(1as,3s,3ar,4r,5s,6r)-4,5-bis(acetyloxy)-3-(furan-3-yl)-3a-methyl-7-methylidene-hexahydroindeno[1,7a-b]oxiren-6-yl]-6,6-dimethyl-5-oxocyclohex-3-en-1-yl]acetate

C30H36O9 (540.2359)

(1s,3bs,4r,5ar,9as,9bs,11ar)-4-(acetyloxy)-1-[(2r)-2-hydroxy-5-oxo-2h-furan-3-yl]-3b,6,6,9a,11a-pentamethyl-2,7-dioxo-4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl acetate

C30H36O9 (540.2359)

(1s,2r,4s,7s,8s,11r,12r,17r,18r,19s)-19-(acetyloxy)-7-(furan-3-yl)-1,8,12,16,16-pentamethyl-5,15-dioxo-3,6-dioxapentacyclo[9.8.0.0²,⁴.0²,⁸.0¹²,¹⁷]nonadec-13-en-18-yl acetate

C30H36O9 (540.2359)

[6-(acetyloxy)-9,12-dihydroxy-5a,8,11a-trimethyl-1-oxo-3-phenyl-6,7,7a,9,10,11,11b,12-octahydro-2,5-dioxatetraphen-8-yl]methyl acetate

C30H36O9 (540.2359)

(1r,2s,3s,4as,6r,8r,8as)-2,6-bis(acetyloxy)-8-[(1e)-2-ethenyl-3-oxobut-1-en-1-yl]-3-hydroxy-4,4,8a-trimethyl-7-oxo-hexahydro-1h-naphthalen-1-yl benzoate

C30H36O9 (540.2359)

8-[(3-ethoxy-6,8-dihydroxy-1-oxo-3-pentyl-4h-2-benzopyran-5-yl)oxy]-6-hydroxy-3-pentylisochromen-1-one

C30H36O9 (540.2359)

[(5as,6s,7ar,8r,9s,11as,11bs,12r)-6-(acetyloxy)-9,12-dihydroxy-5a,8,11a-trimethyl-1-oxo-3-phenyl-6,7,7a,9,10,11,11b,12-octahydro-2,5-dioxatetraphen-8-yl]methyl acetate

C30H36O9 (540.2359)

(2r,3r)-2-{[(2s,3r)-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-7-methoxy-2,3-dihydro-1-benzofuran-5-yl]methyl}-3-[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol

C30H36O9 (540.2359)

19-(acetyloxy)-16-(furan-3-yl)-4-hydroxy-8,8,12,17-tetramethyl-3,11-dioxo-7-oxapentacyclo[10.7.0.0²,⁶.0²,⁹.0¹³,¹⁷]nonadec-13-en-18-yl acetate

C30H36O9 (540.2359)

6-[(1's,2r,4s,6s,13'r,15's)-4,9'-dihydroxy-6,10',15'-trimethyl-6',12',14'-trioxaspiro[oxane-2,5'-tetracyclo[11.3.1.0²,¹¹.0³,⁸]heptadecane]-2',8',10'-trien-13'-ylmethyl]-2,4-dihydroxy-3-methylbenzaldehyde

C30H36O9 (540.2359)

4-(acetyloxy)-1-(2-hydroxy-5-oxo-2h-furan-3-yl)-3b,6,6,9a,11a-pentamethyl-2,7-dioxo-4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl acetate

C30H36O9 (540.2359)

6-{4,9'-dihydroxy-6,10',15'-trimethyl-6',12',14'-trioxaspiro[oxane-2,5'-tetracyclo[11.3.1.0²,¹¹.0³,⁸]heptadecane]-2',8',10'-trien-13'-ylmethyl}-2,4-dihydroxy-3-methylbenzaldehyde

C30H36O9 (540.2359)

(1r,2s,3s,4as,6r,8r,8ar)-2,6-bis(acetyloxy)-8-[(1e)-2-ethenyl-3-oxobut-1-en-1-yl]-3-hydroxy-4,4,8a-trimethyl-7-oxo-hexahydro-1h-naphthalen-1-yl benzoate

C30H36O9 (540.2359)

(1s,2r,4s,7s,8s,10r,11r,12s,17r,19r)-19-(acetyloxy)-7-(furan-3-yl)-1,8,12,16,16-pentamethyl-5,15-dioxo-3,6-dioxapentacyclo[9.8.0.0²,⁴.0²,⁸.0¹²,¹⁷]nonadec-13-en-10-yl acetate

C30H36O9 (540.2359)

(1r,2r,8r,11r,12r,14r,16s,17r,18r,19r)-19-(acetyloxy)-16-(furan-3-yl)-2,7,7,11,17-pentamethyl-5,10-dioxo-6,13-dioxapentacyclo[9.8.0.0²,⁸.0¹²,¹⁴.0¹²,¹⁷]nonadec-3-en-18-yl acetate

C30H36O9 (540.2359)

nimbin (chemical)

C30H36O9 (540.2359)

(3r,3ar,6s,6as,9as,9br)-3-{2-[(6s,6as,9as,9br)-6a-hydroxy-6,9a-dimethyl-2,9-dioxo-4h,5h,6h,9bh-azuleno[4,5-b]furan-3-yl]ethyl}-3,6a-dihydroxy-6,9a-dimethyl-3ah,4h,5h,6h,9bh-azuleno[4,5-b]furan-2,9-dione

C30H36O9 (540.2359)

methyl 2-[(1r)-2-[(1as,3s,3ar,4r,5s,6r,7as)-4,5-bis(acetyloxy)-3-(furan-3-yl)-3a-methyl-7-methylidene-hexahydroindeno[1,7a-b]oxiren-6-yl]-6,6-dimethyl-5-oxocyclohex-3-en-1-yl]acetate

C30H36O9 (540.2359)

2,6-bis(acetyloxy)-8-(2-ethenyl-3-oxobut-1-en-1-yl)-3-hydroxy-4,4,8a-trimethyl-7-oxo-hexahydro-1h-naphthalen-1-yl benzoate

C30H36O9 (540.2359)

(2s,4s,6s,9r,12r,16s,17s,18r,19r)-19-(acetyloxy)-16-(furan-3-yl)-4-hydroxy-8,8,12,17-tetramethyl-3,11-dioxo-7-oxapentacyclo[10.7.0.0²,⁶.0²,⁹.0¹³,¹⁷]nonadec-13-en-18-yl acetate

C30H36O9 (540.2359)

(1s,2r,4s,7s,8s,11r,12r,18r,19s)-19-(acetyloxy)-7-(furan-3-yl)-1,8,12,16,16-pentamethyl-5,15-dioxo-3,6-dioxapentacyclo[9.8.0.0²,⁴.0²,⁸.0¹²,¹⁷]nonadec-13-en-18-yl acetate

C30H36O9 (540.2359)

methyl (3s,4as,5r,6r,6as,7s,11as,11br)-6-(acetyloxy)-3-(benzoyloxy)-4a,5-dihydroxy-4,4,11b-trimethyl-1h,2h,3h,5h,6h,6ah,7h,11h,11ah-phenanthro[3,2-b]furan-7-carboxylate

C30H36O9 (540.2359)

18-(acetyloxy)-7-(furan-3-yl)-1,8,12,16,16-pentamethyl-5,15-dioxo-3,6-dioxapentacyclo[9.8.0.0²,⁴.0²,⁸.0¹²,¹⁷]nonadec-13-en-19-yl acetate

C30H36O9 (540.2359)